- Home
- JLS vs CMMB Comparison
JLS vs CMMB Comparison
Compare JLS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | CMMB |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 20.5M |
| IPO Year | 2009 | 2023 |
Fundamental Metrics
Financial Performance| Metric | JLS | CMMB |
|---|---|---|
| Price | $16.46 | $1.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 26.3K | ★ 142.3K |
| Earning Date | 01-01-0001 | 11-19-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.01 | $1.05 |
| 52 Week High | $18.98 | $3.50 |
Technical Indicators
Market Signals| Indicator | JLS | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 31.21 |
| Support Level | $16.01 | $1.05 |
| Resistance Level | $16.59 | $1.83 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 81.07 | 22.14 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.